Pharmacokinetics of pentoxifylline and its main metabolites in patients with different degrees of heart failure following a single dose of a modified-release formulation

Journal of Clinical Pharmacology

Volumn 53, Issue 1, 2013, Pages 51-57

  Nisi, Alessandra ^a   Panfili, Marco ^a   De Rosa, Giovanni ^a   Boffa, Giovanni ^a   Groppa, Francesca ^a   Gusella, Milena ^b   Padrini, Roberto ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b Laboratory of Pharmacology and Molecular Biology   (Italy)

Author keywords

Chronic heart failure; Drug metabolism; Pentoxifylline; Pharmacokinetics

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DRUG METABOLITE; FUROSEMIDE; PENTOXIFYLLINE; SARTAN DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CREATININE CLEARANCE; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; FEMALE; HEART FAILURE; HUMAN; LIVER FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; SLOW RELEASE FORMULATION; SUSTAINED DRUG RELEASE; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AGED; AGED, 80 AND OVER; DELAYED-ACTION PREPARATIONS; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS;

EID: 84877860471     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011433435     Document Type: Article

References (23)

1. Ward A, Clissold SP. Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs . 1987;34:50-97.
2. Sliwa K, Woodiwiss A, Kone VN, et al. Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study. Circulation . 2004;109:750-755.
3. Sliwa K, Woodiwiss A, Candy G, et al. Effects of pentoxifylline on cytokine profiles and left ventricular performance in patients with decompensated congestive heart failure secondary to idiopathic dilated cardiomyopathy. Am J Cardiol . 2002;90:1118-1122.
4. Skudicky D, Bergemann A, Sliwa K, Candy G, Sareli P. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study. Circulation . 2001;103:1083-1088.
5. Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet . 1998;351:1091-1093.
6. Sliwa K, Woodiwiss A, Libhaber E, et al. C-reactive protein predicts response to pentoxifylline in patients with idiopathic dilated cardiomyopathy. Eur J Heart Fail . 2004;6:731-734.
7. Bahrmann P, Hengst UM, Richartz BM, Figulla HR. Pentoxifylline in ischemic, hypertensive and idiopathic-dilated cardiomyopathy: effects on left-ventricular function, inflammatory cytokines and symptoms. Eur J Heart Fail . 2004;6:195-201.
8. Shaw SM, Shah MKH, Williams SG, Fildes JE. Immunological mechanisms of pentoxifylline in chronic heart failure. Eur J Heart Fail . 2009;11:113-118.
9. Ings RMJ, Nüdemberg F, Burrows JL, Bryce TA. The pharmacokinetics of oxpentifylline in man when administered by constant intravenous infusion. Eur J Clin Pharmacol . 1982;23:539-543.
10. Beermann B, Ings R, Månsby J, Chamberlain J, McDonald A. Kinetics of intravenous and oral pentoxifylline in healthy subjects. Clin Pharmacol Ther . 1985;37:25-28.
11. Niclasson M, Björkman S, Roth B, Jönsson M, Höglund P. Stereoselective metabolism of pentoxifylline in vitro and in vivo in humans. Chirality . 2002;14:643-652.
12. Thompson JA, Bianco JA, Benyunes MC, Neubauer MA, Slattery JT, Fefer A. Phase Ib trial of pentoxifylline and ciprofloxacin in patients treated with interleukin-2 and limphokine-activated killer cell therapy for metastatic renal cell carcinoma. Cancer Res . 1994;54:3436-3441.
13. Mauro VF, Mauro LS, Hageman JH. Comparison of pentoxifylline pharmacokinetics between smokers and non smokers. J Clin Pharmacol . 1992;32:1054-1058.
14. Fantin M, Quintieri L, Kúsz E, et al. Pentoxifylline and its major oxidative metabolites exhibit different pharmacological properties. Eur J Pharmacol . 2006;535:301-309.
15. Rames A, Poirier JM, LeCoz F, et al. Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients. Clin Pharmacol Ther . 1990;47:354-359.
16. Paap CM, Simpson KS, Horton MW, Schaefer KL, Lassman HB, Sack MR. Multiple-dose pharmacokinetics of pentoxifylline and its metabolites during renal insufficiency. Ann Pharmacother . 1996;30:724-729.
17. Shammas FV, Dickstein K. Clinical pharmacokinetics in heart failure: an updated review. Clin Pharmacokinet . 1988;15:94-113.
18. Wagner JG, Nelson E. Kinetics analysis of blood levels and urinary excretion in the absorptive phase after single doses of drugs. J Pharm Sci . 1964;53:1392-1403.
19. Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther . 1975;18:377-390.
20. Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation . 2004;109:1594-1602.
21. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT; Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation . 2003;107:3133-3140.
22. Kurrelmeyer KM, Michael LH, Baumgarten G, et al. Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. Proc Natl Acad Sci U S A . 2000;97:5456-5461.
23. Crouch SPM, Fletcher J. Effect of ingested pentoxifylline in neutrophil superoxide anion production. Infect Immun . 1992;60: 4504-4509.